Neurotrack is building the cognitive health platform of the future, giving people direct access to tools and technology to assess, strengthen, and monitor their cognitive health. The company, based in Silicon Valley, California was co-founded in 2012 by Elli Kaplan, and leading neuroscientists and researchers Stuart Zola, Ph.D., Elizabeth Buffalo, Ph.D., and Cecelia Manzanares. Neurotrack has additional offices in Tokyo and Vancouver.
JAN 2020
Sompo Partnership
Neurotrack partners with Sompo Holdings to launch the Neurotrack Cognitive Health Program to policyholders in Japan.
JUN 2019
Series C Funding
Neurotrack raises $21M in Series C funding round.
APR 2019
Research Grant Awarded
The National Institute of Aging, a division of the U.S. National Institutes of Health, awards Neurotrack with a $3.3M research grant.
NOV 2018
Dai-ichi Life Partnership
Neurotrack partners with Dai-ichi Life to launch its new dementia insurance product.
MAR 2018
Series B Funding
Neurotrack raises $13.7M in Series B funding round.
JAN 2016
Series A Funding
Neurotrack raises $7.5M in Series A funding round.
2012
Neurotrack is Founded
Elli Kaplan co-founds Neurotrack with a mission to give people everywhere the tools to assess their risk for cognitive decline.
Elli Kaplan
Co-Founder and CEO
“What we’re building at Neurotrack matters - to families here and around the world, including mine.”
Sidney Chang
Chief Business Officer
“The financial implications of Alzheimer's are tremendous and daunting. I believe we have the ability to change lives while also making a positive economic impact on our healthcare systems.”
Mitch Underseth
Chief Financial Officer
“We have employees and investors committed to addressing a problem that affects nearly everyone around us.”
Jordan Glenn, Ph.D.
Senior Vice President, Clinical Development
“Alzheimer's isn't about just treatment, but prevention. Neurotrack is working to help stop Alzheimer's Disease before it even begins.”
Jeff Magnusson
Vice President, Engineering
“I have seen Alzheimers and dementia in my own family, and I'm at Neurotrack to leverage technology and find improvements for the millions of people who struggle with it today.”
Daisuke Iwase
Chairman, Asia Pacific
“Our footprint in Japan, the world's fastest aging society, will continue to provide us with invaluable insights to tackle Alzheimer's disease.”
John Harrison, Ph.D.
Principal Consultant
Metis Cognition Ltd.
Michael Ropacki
Vice President of Clinical Development and US Site Head
Oryzon Genomics
Mike Poole, M.D.
Venture Partner
Biomatics Capital
Dorene Rentz, Psy.D.
Co-Director
Center for Alzheimer Research and Treatment, Brigham and Women's Hospital
Stuart Zola Ph.D.
Interim Provost Executive Vice President Academic Affairs
Professor, Psychiatry & Behavioral Sciences
Emory University School of Medicine
Elizabeth Buffalo Ph.D.
Professor, Department of Physiology & Biophysics
University of Washington School of Medicine
Chief, Neuroscience Division
Washington National Primate Research Center
Cecelia Manzanares
Program Manager
Yerkes National Primate Research Center Emory University
